(Q40623022)

22 September 2017

Approach to lipoprotein management in 2001 National Cholesterol Guidelines (English)

1 reference

22 September 2017

1 reference

Scott M Grundy

1

1 reference

PubMed ID

12419477

22 September 2017

National Cholesterol Education Program (NCEP)-The National Cholesterol Guidelines in 2001, Adult Treatment Panel (ATP) III

series ordinal

2

1 reference

PubMed ID

12419477

22 September 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Cardiology

22 September 2017

1 reference

22 September 2017

90

1 reference

22 September 2017

11i-21i

1 reference

22 September 2017

8A

1 reference

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

The value of lowering cholesterol after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Remnant lipoproteins as therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Isolation of remnant particles by immunoseparation: a new approach for investigation of postprandial lipoprotein metabolism in normolipidemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Plasma apolipoprotein B levels predict platelet-dependent thrombosis in patients with coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Current concepts of the pathogenesis of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Coronary heart disease in high-risk populations: lessons from Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Physical activity in the prevention of cardiovascular disease: an epidemiological perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902631-0

10.1016/S0002-9149(02)02631-0

7 January 2021

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

12419477